Gouty Arthritis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutica

As per the report, the gouty arthritis market size has grown strongly in recent years. It will grow from $3.21 billion in 2023 to $3.44 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The gouty arthritis market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16070&type=smp

The Impact Of Obesity On The Gouty Arthritis Market
The increasing prevalence of obesity is expected to propel the growth of the gouty arthritis market going forward. Obesity is a medical disorder characterized by the buildup of extra body fat to the point where it threatens an individual's health and is frequently measured using the body mass index (BMI). The rate of obesity is rising due to increased consumption of high-calorie, processed foods and sedentary lifestyles. Obesity contributes to gouty arthritis by increasing the production of uric acid and reducing the body's ability to excrete it, leading to the accumulation of uric acid crystals in the joints. Additionally, excess body weight places more stress on joints, exacerbating the inflammation and pain associated with gout. For instance, in March 2022, according to the World Health Organization, a Switzerland-based specialized United Nations agency responsible for worldwide public health, around 1 billion individuals, comprising 650 million adults, 340 million teenagers, and 39 million children, were classified as obese, with this figure continuing to rise. Furthermore, the projections indicate that by 2025, approximately 167 million adults and children will suffer health consequences due to excess weight. Therefore, the increasing prevalence of obesity is driving the growth of the gouty arthritis market.

Innovative Options In Gouty Arthritis Treatment
Major companies operating in the gouty arthritis market are increasing their efforts to develop novel products, such as cortrophin gel, to provide more effective and targeted therapies for managing the condition. Cortrophin gel, also known as repository corticotropin injection, is a purified form of the adrenocorticotropic hormone (ACTH). It is used to treat various inflammatory and autoimmune conditions, including gouty arthritis. For instance, in October 2023, ANI Pharmaceuticals, a US-based pharmaceutical company, received approval from the Food and Drug Administration for a new 1-mL vial size of Purified Cortrophin Gel. This product is intended for the adjunctive treatment of certain patients experiencing acute gouty arthritis flares. Cortrophin Gel is currently the only FDA-approved adrenocorticotropic hormone (ACTH) therapy indicated for treating appropriate patients with acute gouty arthritis flares.

The gouty arthritis market covered in this report is segmented -

1) By Type: Acute Gouty Arthritis, Chronic Gouty Arthritis
2) By Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Reliever, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosurics, Others Treatments
3) By Diagnosis: Joint Fluid Test, Blood Test, X-Ray Imaging, Ultrasound, Dual Energy Computed Tomography (CT) Scan, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16070&type=discount

Major companies operating in the gouty arthritis market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Horizon Therapeutics plc, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Gouty Arthritis Market Report Structure
3. Gouty Arthritis Market Trends And Strategies
4. Gouty Arthritis Market - Macro Economic Scenario
5. Gouty Arthritis Market Size And Growth
…..
27. Gouty Arthritis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.